ArticleJournal of the American Academy of Dermatology2012
Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare.
Article in Journal of the American Academy of Dermatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- A Systematic Review of the Progression of Cutaneous Lupus to Systemic Lupus Erythematosus.Frontiers in immunology · 2022Pooled it
- Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial.Journal of the American Academy of Dermatology · 2014Trial
- Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus.Arthritis research & therapy · 2012Trial
- An update on the management of refractory cutaneous lupus erythematosus.Frontiers in medicine · 2022Review
- Effects of targeting the transcription factors Ikaros and Aiolos on B cell activation and differentiation in systemic lupus erythematosus.Lupus science & medicine · 2021Article
- Cutaneous Lupus Erythematosus: Progress and Challenges.Current allergy and asthma reports · 2020Review
- Review
- Current Insights Into The Management Of Discoid Lupus Erythematosus.Clinical, cosmetic and investigational dermatology · 2019Article
- Lenalidomide: An Alternative Treatment for Refractory Behçet's Disease and Relapsing Polychondritis.European journal of case reports in internal medicine · 2019Article
- Multiple Myeloma Presenting with Autoimmune Autonomic Ganglionopathy.Internal medicine (Tokyo, Japan) · 2017Article
- Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus.Lupus · 2017Article
- Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects.Expert review of clinical immunology · 2016Review
- Pragmatic approaches to therapy for systemic lupus erythematosus.Nature reviews. Rheumatology · 2014Review
- Update on pathogenesis and treatment of CLE.Current opinion in rheumatology · 2013Review
- Cutaneous lupus erythematosus: diagnosis and treatment.Best practice & research. Clinical rheumatology · 2013Review
- Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria.The Journal of clinical and aesthetic dermatology · 2013Article
- Measurement of disease severity in cutaneous autoimmune diseases.F1000prime reports · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundLenalidomide is a thalidomide analogue that may serve as an adjunctive therapy for treatment-refractory cutaneous lupus erythematosus (CLE).
objectivesWe evaluate the use of lenalidomide in CLE and describe the skin and circulating leukocyte profile of treatment-refractory patients before and after treatment.
methodsFive subjects were treated with lenalidomide in an unblinded open-label study. Immunohistochemistry of skin was performed for T-cell markers, glycosaminoglycans, and CXCL10, an interferon-inducible chemokine, before and after treatment. Immunophenotyping and measurement of interferon-inducible genes from peripheral blood mononuclear cells was also performed before and after treatment.
resultsFour subjects demonstrated clinical improvement of their skin, however one of these responders subsequently developed symptoms of systemic lupus erythematosus. Small changes in rare circulating leukocyte subsets, plasmacytoid dendritic cells, and regulatory T cells were observed with treatment and may correlate with clinical response. Treatment was associated with increased circulating HLA-DR expression and decreased markers of interferon-mediated pathways, regardless of clinical response. LIMITATIONS: Our results are limited by small sample size and the measurement of rare populations of circulating cell subsets.
conclusionsLenalidomide may have usefulness as therapy for severe, treatment-refractory CLE. However, our preliminary data suggest that lenalidomide may activate T cells and trigger systemic disease in some patients with CLE. We also saw a different histologic and circulating leukocyte phenotype in the nonresponding subject. Further characterization of the skin and circulating leukocyte profile of treatment-refractory patients will improve our understanding of CLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.